Law & Regulation
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
The notice said "overall benefit-risk profile" as well as its "potential public health impact" will be the focus of the session.
The post FDA to weigh…
The Food and Drug Administration announced Wednesday it will convene a public advisory committee meeting next month to evaluate a drug application for MDMA as a treatment for post-traumatic stress disorder.
In a federal notice, the FDA said the Psychopharmacologic Drugs Advisory Committee will discuss the overall benefit-risk profile and potential public health impact of Lykos Therapeutics‘ application for MDMA capsules on June 4. The committee provides nonbinding recommendations to the agency.
Lykos Therapeutics was previously known as MAPS Public Benefit Corp.
The daylong meeting in Silver Spring, Maryland, will be open to the public both in-person and remotely. It will focus on Lykos’ new drug application for MDMA capsules “for the proposed indication of treatment of post-traumatic stress disorder,” according to the FDA notice.
The committee’s expert advisers will weigh clinical data on the drug’s safety and efficacy. Presentations from FDA staff, the company, and public comments are expected before the panel votes on a recommendation regarding approval.
If cleared, MDMA (midomafetamine) would continue to be a federally controlled substance because of its psychedelic properties, but it could represent a new avenue for treating PTSD, a difficult-to-treat condition affecting millions of Americans.
MDMA was popularized as a party drug in the 1980s but has shown promise in clinical trials for helping people with PTSD when combined with counseling. It produces feelings of euphoria, emotional warmth, and distorted perception of time.
The FDA previously designated MDMA as a “breakthrough therapy” to expedite its development and review. A decision on Lykos’ application is expected by late summer.
The agency will take public comments on the application until June 3. Meeting background materials will be posted online by June 2.
The post FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting appeared first on Green Market Report.
fda psychedelic mdma-
Psychedelics1 week ago
Optimi Health Provides Corporate Update
-
Law & Regulation7 days ago
Relmada loses another $21.8M, makes progress with clinical trials
-
Law & Regulation1 week ago
Horizons talk shifts from investors to insurance
-
Law & Regulation1 week ago
DEA psychedelics ban hearing halted by lawsuit
-
Psychedelics6 days ago
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
-
Psychedelics5 days ago
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
-
Law & Regulation6 days ago
AbbVie, Gilgamesh Pharmaceuticals enter psychiatric drug deal
-
Psychedelics6 days ago
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine